angiotensin II (AT1) receptor

Every compound in the sci-wiki that affects angiotensin ii (at1) receptor; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

3 sourced · 0 reference

←angiotensin ii (at1) receptor3/3

Nootropic

Losartan

Losartan is an angiotensin II receptor blocker (ARB) used mainly to treat high blood pressure and to protect the kidneys in people with type 2 diabetes. It was the first drug of its class to reach the market, working by blocking the angiotensin II type 1 (AT1) receptor so that blood vessels relax and the heart and kidneys face less strain. Taken by mouth as the potassium salt, it is now a widely available, low-cost generic on the World Health Organization list of essential medicines.

2 outlets

Blend

Losartan + Hydrochlorothiazide

Losartan/hydrochlorothiazide is a fixed-dose combination antihypertensive that pairs the angiotensin II receptor blocker losartan with the thiazide diuretic hydrochlorothiazide in a single tablet. Sold under names such as Hyzaar, it is used to lower blood pressure when one drug is not enough. The two ingredients act through complementary mechanisms, so the combination usually lowers blood pressure more than either component on its own.

1 outlet

ARB

Valsartan

Valsartan is an angiotensin II receptor blocker that selectively antagonizes the AT1 receptor, relaxing blood vessels and blunting the renin-angiotensin-aldosterone system without the cough associated with ACE inhibitors. It carries an unusually deep clinical-trial pedigree: Val-HeFT established its benefit when added to standard heart-failure therapy, VALIANT showed it was as effective as captopril after myocardial infarction, and VALUE evaluated it in high-risk hypertension, while the NAVIGATOR trial found it modestly reduced progression to type 2 diabetes in people with impaired glucose tolerance. It is a component of sacubitril/valsartan, the angiotensin receptor-neprilysin inhibitor that outperformed enalapril in the PARADIGM-HF trial and reshaped heart-failure care. Preclinical work has also suggested a neuroprotective angle, with valsartan lowering brain amyloid-beta and improving spatial learning in a mouse model of Alzheimer disease.

1 outlet